Congress Materials – Myasthenia Gravis Foundation of America (MGFA 2026)
2026 Myasthenia Gravis Foundation of America | Sep 29 | Orlando, FL
AChR Autoantibody Detection and Therapeutic Assessment of Nipocalimab in Seronegative Patients with Myasthenia Gravis in Vivacity-MG3
Silke Miller, Gallen Triana-Baltzer, Hans Frykman, Anna Mammel, Pankaj Kumar, Marie Fitzgibbon, Michael Kutch, Laura Green, Sindhu Ramchandren, Matteo Gastaldi
This document will be available on Sep 29th 2026
Age-Related Differences in Persistence with Standard-of-Care Treatment for Generalized Myasthenia Gravis in the United States
Jacqueline Pesa, Maryia Zhdanava, Louis Jackson, Porpong Boonmak, Anabelle Tardif-Samson, Gokce Gokkoca, Dominic Pilon
This document will be available on Sep 29th 2026
Assessing Relationship Between Igg-Levels And Infection Rate In Nipocalimab-Treated Patients With Generalized Myasthenia Gravis (VIVACITY-MG3)
Ghazala Hayat, Ricardo Rojo Cella, Robert Edwards, Marie Fitzgibbon, Robert Gordon, M. Sc, Wim Noel, Zia Choudhry, Kavita Gandhi, Sindhu Ramchandren, Kevin L. Winthrop, Carlo Antozzi
This document will be available on Sep 29th 2026
Assessment of sustained health-related-quality-of-life in Phase 3 Vivacity-MG3 Trial of Nipocalimab versus Placebo in Generalized Myasthenia Gravis
John Vissing, Kavita Gandhi, Sheryl Pease, Ibrahim Turkoz, Marie Fitzgibbon, Geoffroy Coteur, Wisam Karmous, Nolan Campbell, Sindhu Ramchandren, Elena Corts-Vicente
This document will be available on Sep 29th 2026
Assessment of the Relationship Between IgG Levels and Infection Rate in Nipocalimab Treated Patients with Generalized Myasthenia Gravis in Vivacity-MG3 Study
Rosemarie Walch, Marie Fitzgibbon, Nolan Campbell, Carly J Paoli, Sheryl Pease, Ibrahim Turkoz, Sindhu Ramchandren, Mazen M. Dimachkie
This document will be available on Sep 29th 2026
Clinical Outcomes, Healthcare Resource Utilization, and Costs Before and After Immunoglobulin Initiation in Generalized Myasthenia Gravis
Jacqueline Pesa, Maryia Zhdanava, Louis Jackson, Porpong Boonmak, Anabelle Tardif-Samson, Fanny Jiang, Dominic Pilon
This document will be available on Sep 29th 2026
Corticosteroid Usage in Patients with Generalized Myasthenia Gravis Receiving Nipocalimab: Findings from Open-Label Extension Phase of the Phase 3 Vivacity-MG3 Study
Yuebing Li, Kavita Gandhi, Wisam Karmous, Marie Fitzgibbon, Ibrahim Turkoz, I-Ching Tsai, Zia Choudhry, Wim Noel, Louis Jackson, Sindhu Ramchandren, Hiroyuki Murai
This document will be available on Sep 29th 2026
Corticosteroid Use in Nipocalimab-treated Japanese Patients with Generalized Myasthenia Gravis: Phase 3 VIVACITY-MG3 Open-Label Extension Study
Carlo Antozzi, Kavita Gandhi, Ibrahim Turkoz, Michael Kutch, Marie Fitzgibbon, Sindhu Ramchandren, Hiroyuki Murai
This document will be available on Sep 29th 2026
Digital Gait Characteristics as Indicators of Muscle Strength in Chronic Inflammatory Demyelinating Polyneuropathy
Rana Zia, Ur Rehman, Philippe Linscheid, Bahador Marzban, Meenakshi Chatterjee, Junrui Di, Charmaine Demanuele, Lisa Ford, Matthew Boice, Anahita Kyani
This document will be available on Sep 29th 2026
Effect of Nipocalimab on Pathogenic IgG and Circulating Immune Complex Levels: A Role in Myasthenia Gravis-Activities of Daily Living Score Improvement in Patients With Generalized Myasthenia Gravis
Ruben Faelens, Matthias Bruckner, Jingyue Xi, Yanfei Zhang, Silke Miller, Sindhu Ramchandren, Marie Fitzgibbon, Sarah Hoffmann
This document will be available on Sep 29th 2026
Effect of Nipocalimab on Pathogenic IgG and Complement Activity in Patients with Seropositive gMG: Exploratory Analysis in VIVACITY-MG-3 study
Silke Miller, Jingyue Xi, Yanfei Zhang, Ruben Faelens, Marie Fitzgibbon, Sindhu Ramchandren, Sarah Hoffmann
This document will be available on Sep 29th 2026
Effect of Nipocalimab on Sustained Disease Control in Anti-muscle-specific Tyrosine Kinase-antibody Positive Patients in the Vivacity-MG3 Study
Rosemarie Walch, Marie Fitzgibbon, Nolan Campbell, Carly J Paoli, Ibrahim Turkoz, Sindhu Ramchandren, Mazen M. Dimachkie
This document will be available on Sep 29th 2026
Effect of Nipocalimab on Sustained Disease Control in Patients who Responded After Week-2 of Treatment Initiation: Post-Hoc Analysis of the Vivacity-MG3 Study
Michael Weiss, Carly J. Paoli, Ibrahim Turkoz, Marie Fitzgibbon, Michael Kutch, Carlo Antozzi
This document will be available on Sep 29th 2026
Effect of Nipocalimab on Sustained Myasthenia Gravis Control During Infections: Post-hoc Analysis of the Vivacity-MG3 Study
Carlo Antozzi, Goncalo M.C. Rodrigues, Marie Fitzgibbon, Robert Edwards, Ibrahim Turkoz, Michael Kutch, Sindhu Ramchandren, Ghazala S. Hayat
This document will be available on Sep 29th 2026
Efficacy and Safety of Nipocalimab in Patients Switching from 15 mg/kg Every-2-Week to 30 mg/kg Every-4-Week Dosing During the VIVACITY-MG3 Open-Label Extension
Tuan Vu, Marie Fitzgibbon, Kavita Gandhi, Nolan Campbell, Yaowei Zhu, Jocelyn H. Leu, Ibrahim Turkoz, Sindhu Ramchandren
This document will be available on Sep 29th 2026
Efficacy of Nipocalimab in Adult Patients with None-to-Mild Ocular Manifestations of gMG in Phase 3 VIVACITY-MG3
Kristl G. Claeys, Kavita Gandhi, Ibrahim Turkoz, Michael Kutch, Marie Fitzgibbon, Sindhu Ramchandren
This document will be available on Sep 29th 2026
Efficacy of Nipocalimab in Patients Early in Their Disease Course of Generalized Myasthenia Gravis: Post Hoc Analysis of VIVACITY-MG3
Carlo Antozzi, Wim Noel, Marie Fitzgibbon, Wisam Karmous, Kavita Gandhi, Ibrahim Turkoz, Michael Kutch, Sindhu Ramchandren, Elena Corts-Vicente
This document will be available on Sep 29th 2026
Efficacy of Nipocalimab in Patients with Lower Baseline Score of Myasthenia Gravis Activity of Daily Living in VIVACITY-MG3 study
Carlo Antozzi, Wim Noel, Wisam Karmous Marie Fitzgibbon, Kavita Gandhi, Ibrahim Turkoz, Michael Kutch, Sindhu Ramchandren
This document will be available on Sep 29th 2026
Factors Associated with Recurrent Clinical Events among Pediatric Generalized Myasthenia Gravis Patients in the United States
Jacqueline Pesa, Zhiwen Liu, Louis Jackson, Liang-Yuan Lin, Raghav Govindarajan
This document will be available on Sep 29th 2026
Frequency of Sustained Response to Nipocalimab Versus Placebo Based on MG-ADL and QMG Scales in the Phase 3 Vivacity-MG3 Study
Shahar Shelly, Marie Fitzgibbon, Ibrahim Turkoz, Kavita Gandhi, Sindhu Ramchandren, Constantine Farmakidis
This document will be available on Sep 29th 2026
Healthcare Costs in Commercially Enrolled Pediatric Patients with Generalized Myasthenia Gravis in the United States
Jacqueline Pesa, Zhiwen Liu, Louis Jackson, Liang-Yuan Lin, Raghav Govindarajan
This document will be available on Sep 29th 2026
Immunogenicity Assessment With Nipocalimab Treatment In Patients With Generalized Myasthenia Gravis
Yaowei Zhu, Eleni Caratzas, Jocelyn H. Leu, Korin Cofsky, Sindhu Ramchandren, Navin Goyal
This document will be available on Sep 29th 2026
Indirect comparison of Nipocalimab Safety Versus Fcrn Blockers, C5 Complement Inhibitors, Rituximab and IVIg in Generalized Myasthenia Gravis
Saiju Jacob, Brian Hutton, Suzy Van Sanden, Tom Denee, Wisam Karmous, Joris Diels, Kavita Gandhi, Carly J. Paoli, Mahmoud Hashim, Nils Erik Gilhus
This document will be available on Sep 29th 2026
Lived Experiences of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Global Patient and Caregiver Perspectives
Betsy Blake, Nancy Di Salvo, Lisa Shea, Maartje Mangelaars, Marie Fitzgibbon, Claudia Sommer
This document will be available on Sep 29th 2026
Long-term safety and efficacy of nipocalimab: Approximately 2 years follow-up results from the open-label extension phase of Vivacity-MG3 study
Carlo Antozzi, Tuan Vu, Sindhu Ramchandren, Richard J. Nowak, Constantine Farmakidis, Kumaraswamy Sivakumar, Panna Sanga, Ibrahim Turkoz, Yaowei Zhu, Marie Fitzgibbon, Michel Burcklen
This document will be available on Sep 29th 2026
Nipocalimab in chronic inflammatory demyelinating polyneuropathy: Updated diagnostic adjudication findings from the Phase 2/3 ARISE study
Kenneth Gorson, Thomas Harbo, Jonathan Katz, Richard A. Lewis, Bob Murray, Phillippe Linscheid, Mojgansadat Borghei, Lisa Ford
This document will be available on Sep 29th 2026
Pregnancy Enhanced Tracking with Neonatal and Infant Assessment (PETUNIA): Design of a Safety Study for Nipocalimab in Generalized Myasthenia Gravis
Neelam Goyal, Christopher J Robinson, Christiane Schneider-Gold, Diana E Clements, Marie Fitzgibbon, Ibrahim Turkoz, Lorraine S Gentner, Toyin Adewole, Lisa Schwartz, Melanie H Jacobson
This document will be available on Sep 29th 2026
Quality of Life in Generalized Myasthenia Gravis Patients Achieving Sustained versus Transient Clinical Outcomes in the Phase 3 Vivacity-MG3 Trial
John Vissing, Carlo Antozzi, Kelly G Gwathmey, Kavita Gandhi, Ibrahim Turkoz, Sheryl Pease, Nolan Campbell
This document will be available on Sep 29th 2026
Quality of Life in Patients with Generalized Myasthenia Gravis Achieving Sustained vs Transient Minimal Symptom Expression in the Phase 3 Vivacity-MG3 Trial
Elena Corts Vicente, Nolan Campbell, Kavita Gandhi, Marie Fitzgibbon, Ibrahim Turkoz
This document will be available on Sep 29th 2026
Retrospective Review of Treatment Switches to Nipocalimab in generalized Myasthenia Gravis: Real World Healthcare Provider Perspectives
Kutz C, Pesa J, Bercury-Russell K, Campbell N
This document will be available on Sep 29th 2026
Symptom severity assessment using MG-ADL items and domains in Active-Treatment Phase: vibrance-mg Phase 2/3 Study of Nipocalimab in Adolescents with Generalized Myasthenia Gravis
Tuan Vu, Marie Fitzgibbon, Ibrahim Turkoz, Dan Huang, Carly J. Paoli, Jelena Dukovski
This document will be available on Sep 29th 2026
Two Year Follow-Up Results of Nipocalimab in Adolescents With Generalized Myasthenia Gravis During Active-Treatment and Long-Term Extension Phases: VIBRANCE-MG Phase 2/3 Study
Tuan Vu, Jonathan Strober, Saunder Bernes, Akiyuki Uzawa, Yasuhiro Kimoto, Keiko Ishigaki, Erin Neil Knierbein, Hideki Shimomura, Erik Niks, Maria Mazurkiewicz-Beldzinska, Jelena Dukovski, Amita Singh, Dan Huang, Yaowei Zhu, Sindhu Ramchandren
This document will be available on Sep 29th 2026
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.